AKRO Akero Therapeutics Inc

Price (delayed)

$10.39

Market cap

$363.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.2

Enterprise value

$214.65M

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights
AKRO's debt is down by 14% year-on-year and by 4.3% since the previous quarter
Akero Therapeutics's quick ratio has shrunk by 70% YoY
AKRO's equity is down by 40% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
35.02M
Market cap
$363.89M
Enterprise value
$214.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$111.72M
EBITDA
-$111.47M
Free cash flow
-$84.21M
Per share
EPS
-$3.2
Free cash flow per share
-$2.41
Book value per share
$4.19
Revenue per share
$0
TBVPS
$4.85
Balance sheet
Total assets
$169.89M
Total liabilities
$23.35M
Debt
$1.26M
Equity
$146.54M
Working capital
$145.84M
Liquidity
Debt to equity
0.01
Current ratio
7.6
Quick ratio
7.48
Net debt/EBITDA
1.34
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-54%
Return on equity
-60.8%
Return on invested capital
-367.3%
Return on capital employed
-75.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
-3.08%
1 week
-14.56%
1 month
26.25%
1 year
-63.47%
YTD
-50.87%
QTD
-26.78%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$111.81M
Net income
-$111.72M
Gross margin
N/A
Net margin
N/A
AKRO's net income is down by 36% YoY and by 11% QoQ
Akero Therapeutics's operating income has decreased by 35% YoY and by 11% from the previous quarter

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
2.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 27% YoY and by 11% QoQ
AKRO's equity is down by 40% year-on-year and by 13% since the previous quarter
The stock's P/B is 36% below its last 4 quarters average of 3.9

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has shrunk by 68% QoQ
Akero Therapeutics's return on equity has shrunk by 65% YoY and by 26% QoQ
The ROA has plunged by 55% YoY and by 22% from the previous quarter

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The total liabilities has soared by 101% year-on-year but it is down by 12% since the previous quarter
The current ratio has dropped by 70% year-on-year
AKRO's debt is 99% smaller than its equity
AKRO's equity is down by 40% year-on-year and by 13% since the previous quarter
AKRO's debt is down by 14% year-on-year and by 4.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.